4 Stocks Dragging In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 90 points (0.6%) at 15,153 as of Tuesday, Sept. 10, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,842 issues advancing vs. 1,092 declining with 95 unchanged.

The Drugs industry currently sits up 0.3% versus the S&P 500, which is up 0.5%. On the negative front, top decliners within the industry include Vertex Pharmaceuticals ( VRTX), down 2.4%, and Biomarin Pharmaceutical ( BMRN), down 2.2%. A company within the industry that increased today was Sanofi ( SNY), up 1.4%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Neurocrine Biosciences ( NBIX) is one of the companies pushing the Drugs industry lower today. As of noon trading, Neurocrine Biosciences is down $4.93 (-29.5%) to $11.77 on heavy volume. Thus far, 6.6 million shares of Neurocrine Biosciences exchanged hands as compared to its average daily volume of 595,100 shares. The stock has ranged in price between $11.31-$12.17 after having opened the day at $12.05 as compared to the previous trading day's close of $16.70.

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Neurocrine Biosciences has a market cap of $1.1 billion and is part of the health care sector. Shares are up 115.4% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Neurocrine Biosciences a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Neurocrine Biosciences as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Neurocrine Biosciences Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Valeant Pharmaceuticals International ( VRX) is down $1.26 (-1.2%) to $100.07 on light volume. Thus far, 471,379 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $100.01-$101.74 after having opened the day at $101.50 as compared to the previous trading day's close of $101.33.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $33.3 billion and is part of the health care sector. Shares are up 67.7% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Biogen Idec ( BIIB) is down $2.04 (-0.9%) to $226.82 on light volume. Thus far, 363,321 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $224.79-$230.35 after having opened the day at $230.00 as compared to the previous trading day's close of $228.86.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $53.5 billion and is part of the health care sector. Shares are up 53.8% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Amgen ( AMGN) is down $1.22 (-1.1%) to $110.45 on light volume. Thus far, 1.2 million shares of Amgen exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $110.42-$112.60 after having opened the day at $112.32 as compared to the previous trading day's close of $111.67.

Amgen, the world's largest independent biotechnology company, was founded in Thousand Oaks, California in 1980 as AMGen (Applied Molecular Genetics). Amgen has a market cap of $83.6 billion and is part of the health care sector. Shares are up 28.8% year to date as of the close of trading on Monday. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?